Literature DB >> 10342881

A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1.

N Bühlmann1, K Leuthäuser, R Muff, J A Fischer, W Born.   

Abstract

Adrenomedullin (ADM) and alpha- and beta-calcitonin (CT) gene-related peptide (alpha-, betaCGRP) are structurally related vasodilatory peptides with homology to CT and amylin. An originally orphan human CT receptor-like receptor (hCRLR) is a Gs protein-coupled CGRP or ADM receptor when coexpressed with recently identified human single transmembrane domain receptor activity modifying proteins 1 (hRAMP1) or -2 (hRAMP2), respectively. Here, the function of the rat CRLR homologue (rCRLR) has been investigated in rat osteoblast-like UMR-106 cells and in COS-7 cells, in the absence and presence of hRAMP1 and -2 and combinations thereof. Transient expression of rCRLR in UMR-106 cells revealed an ADM receptor, and [125I]rat (r) ADM binding was enhanced with hRAMP2 and inhibited by 50% when hRAMP1 was coexpressed. Detectable [125I]h alphaCGRP binding required the presence of hRAMP1, and the expression of CGRP binding sites was unaffected by coexpressed hRAMP2. Specificity of ADM binding sites in [125I]rADM binding inhibition experiments was reflected by an over 1000-fold higher potency of rADM [half-maximal effective concentration = 0.19 +/- 0.05 nM (mean +/- SEM, n = 4)], compared with r alphaCGRP and r betaGRP, to induce a cAMP-responsive luciferase reporting gene (CRE-luc). In rCRLR and hRAMP1 cotransfected cells, expressing predominantly CGRP binding sites, r betaCGRP, r alphaCGRP, and rADM induced CRE-luc with half-maximal effective concentration of 0.27 +/- 0.17 nM, 0.37 +/- 0.27 nM, and 1.4 +/- 0.9 nM, respectively. In COS-7 cells, the results were comparable, but rCRLR required coexpressed hRAMP2 for ADM receptor function. This is consistent with higher levels of endogenous RAMP2 encoding messenger RNA in UMR-106, compared with COS-7 cells. In conclusion, the recognition of RAMP1 and -2 as mediators of CRLR expression as a CGRP or ADM receptor has been extended, with evidence that endogenous RAMP2 is sufficient to reveal an ADM receptor in UMR-106 cells. Inhibition of RAMP2-evoked ADM receptor expression by RAMP1 and generation of a CGRP receptor is consistent with competitive interactions of the different RAMPs with rCRLR.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10342881     DOI: 10.1210/endo.140.6.6783

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  22 in total

1.  CGRP and adrenomedullin binding correlates with transcript levels for calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) in rat tissues.

Authors:  P Chakravarty; T P Suthar; H A Coppock; C G Nicholl; S R Bloom; S Legon; D M Smith
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with 'Compound 1' (WO98/11128), a non-peptide antagonist.

Authors:  P Hasbak; A Sams; S Schifter; J Longmore; L Edvinsson
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

3.  Receptor-activity-modifying protein 1 forms heterodimers with two G-protein-coupled receptors to define ligand recognition.

Authors:  K Leuthäuser; R Gujer; A Aldecoa; R A McKinney; R Muff; J A Fischer; W Born
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

Review 4.  The pharmacology of adrenomedullin receptors and their relationship to CGRP receptors.

Authors:  Debbie L Hay; Alex C Conner; Stephen G Howitt; David M Smith; David R Poyner
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

5.  Increased alphaCGRP potency and CGRP-receptor antagonist affinity in isolated hypoxic porcine intramyocardial arteries.

Authors:  Philip Hasbak; Karen Eskesen; Søren Schifter; Lars Edvinsson
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

6.  Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery.

Authors:  L Edvinsson; E Nilsson; I Jansen-Olesen
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

Review 7.  CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?

Authors:  C S Walker; D L Hay
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 8.  Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles.

Authors:  Debbie L Hay; Augen A Pioszak
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

9.  CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS.

Authors:  D L Hay; S G Howitt; A C Conner; M Schindler; D M Smith; D R Poyner
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

10.  Dissection of functional residues in receptor activity-modifying proteins through phylogenetic and statistical analyses.

Authors:  Alfonso Benítez-Páez; Sonia Cárdenas-Brito
Journal:  Evol Bioinform Online       Date:  2008-04-28       Impact factor: 1.625

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.